Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features Academic Article uri icon

Overview

MeSH Major

  • Lung Neoplasms
  • Oncolytic Virotherapy
  • Picornaviridae
  • Small Cell Lung Carcinoma

abstract

  • Intravenous SVV-001 administration in patients is well tolerated at doses up to 10(11) vp/kg, with predictable viral clearance kinetics, intratumoral viral replication, and evidence of antitumor activity in patients with small cell lung cancer. Phase II clinical evaluation in small cell lung cancer is warranted, and has been initiated.

publication date

  • February 15, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5317273

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-10-1706

PubMed ID

  • 21304001

Additional Document Info

start page

  • 888

end page

  • 95

volume

  • 17

number

  • 4